Life Science REIT's Oxford lab lease to OET hits £46.50/sq ft record in 10-year biotech deal, boosting ERV to £1.5m.
This article covers information on Life Science REIT PLC.
LON:LABSAnother day, another milestone in the UK’s life sciences property boom. Today’s RNS from Life Science REIT (LABS) isn’t just about bricks, mortar, and pipettes – it’s a masterclass in strategic positioning within one of property’s hottest subsectors. Let’s unpack why this Oxford Technology Park (OTP) deal with Oxford Expression Technologies (OET) deserves investors’ attention.
This isn’t some fresh-faced startup. OET’s been turning heads since 2006 with its flashBAC™ technology – the sort of innovation that makes Big Pharma firms sit up and take notice. Their move from Oxford Brookes’ Bioinnovation Hub to OTP’s Innovation Quarter (IQ) tells us two things:
“The OTP site provides everything we need to support the continued growth and success of OET.”
– Linda King, OET Founder
Life Science REIT’s Innovation Quarter is playing a clever game. While everyone chases mega-lab developments, they’re cornering the market in:
Since September 2024’s HY results, LABS has converted £1.5m ERV – equivalent to:
This deal reinforces three key sector drivers:
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
60 viewsLikes
No ratings yet
“OTP can cater to demands throughout the life cycle – we look forward to growing with OET.”
– Ian Harris, Ironstone Asset Management
Beyond the press release gloss, this deal:
While the life sciences property gold rush continues, LABS is demonstrating that smart niche strategies (like targeting scale-up phase companies) can deliver outsized returns. As OET settles into its new Oxford digs, investors might want to keep an eye on whether this rental record becomes the park’s new normal.
Now, if you’ll excuse me, I’m off to see if my local co-working space does CL2 lab spec conversions…
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.